Colliers completes acquisition of Pangea
December 02, 2022 04:00 ET
|
Colliers International Group Inc
TORONTO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) has completed its previously announced acquisition...
Colliers completes Nordic acquisition of Pangea Property Partners
December 02, 2022 04:00 ET
|
Colliers EMEA Limited
LONDON, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), announced today that it has concluded its...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022 23:41 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
Shoals Technologies Group, Inc. Announces Pricing of Upsized Offering of 26,000,000 Shares of Class A Common Stock
December 01, 2022 23:29 ET
|
Shoals Technologies Group
PORTLAND, Tenn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (Nasdaq: SHLS) (the “Company”) today announced the pricing of its upsized underwritten public offering of an...
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
December 01, 2022 20:26 ET
|
Anavex Life Sciences Corp.
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADLKey Secondary Endpoint CDR-SB Also Met, Demonstrating...
Theratechnologies Announces Update from Ongoing TH1902 Study
December 01, 2022 18:30 ET
|
Theratechnologies
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
Theratechnologies fait le point concernant l’essai clinique en cours sur le TH1902
December 01, 2022 18:30 ET
|
Theratechnologies
MONTRÉAL, 01 déc. 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
CVG Announces Participation in the Sidoti Virtual Small-Cap Investor Conference
December 01, 2022 18:30 ET
|
Commercial Vehicle Group, Inc.
NEW ALBANY, Ohio, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CVG (NASDAQ: CVGI) announced today that Harold Bevis, President and Chief Executive Officer, and Andy Cheung, Executive Vice President and Chief...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2022 17:45 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
December 01, 2022 17:34 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...